MK-0646 IMPACT Study: MK-0646, Insulin Growth Factor 1 Receptor Antibody in Stage IIIB or IV Metastatic Non-Squamous Lung Cancer, Combined With Pemetrexed (Alimta) and Cisplatin, a Randomized Phase II Trial.

NCT00799240 Phase 2 COMPLETED

This study will compare the rate of chemotherapy: pemetrexed and cisplatin compared with the combination of pemetrexed/cisplatin with MK-0646. The other purposes are to determine how long we can control the cancer growth and toxicity and safety of the combination. Laboratory research with the tumor tissue and blood obtained will be done to assess IGF-1R expression and related markers and correlate with response and survival.

Details

Lead sponsor	University of Kansas
Phase	Phase 2
Status	COMPLETED
Enrolment	27
Start date	2009-06
Completion	2014-07

Conditions

• Non Small Cell Lung Cancer

Interventions

• Arm A: Pemetrexed Cisplatin
• Arm B Pemetrexed, Cisplatin and MK-0646

Primary outcomes

• Compare response rate between the two arms. — 31 months

Countries

United States